Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First-in-Human trial tests 'Off-the-Shelf' cell therapy for Tough-to-Treat cancers

NCT ID NCT07366658

Summary

This is the first time researchers are testing a new cell therapy called NEUK203-13 in people. The study aims to see if it is safe and can help control tumors in patients with advanced small cell lung cancer or other neuroendocrine tumors that have stopped responding to standard treatments. The therapy uses specially engineered immune cells designed to find and attack cancer cells, and it's given to a small group of 7-9 patients to check safety first.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Hospital of CICAMS

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.